comprehensive -WSS

comprehensive

author：focus 2025-09-27 10:02:01 - browse：369

Is biotech back from its downturn? Can Nvidia solve biology? And is it wise to do a deal on a party bus?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Recording from the J.P. Morgan Healthcare Conference, we discuss how a spate of deals and some intermittent sunshine seem to have brightened the outlook for biotech at the outset of 2024. We also talk about the latest twist in the Sarepta Therapeutics saga, a ubiquitous dealmaker, and life on the party circuit.

For more on what we cover, here’s the news on Sarepta; here’s more on Nvidia; here’s the story on Centerview; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： How to protect coverage of PrEP

WSS

Sophia Smith scores twice for US in in 3

Heart disease and mental health: A look at cardiac psychology

New Medicare drug pricing powers could soon be upended in court

4 missing after record

PrEP can help anyone prevent HIV. Why do so few people take it?

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

focus

comprehensive

entertainment

Bright Health sells Medicare Advantage business to Molina

Caregivers of transplant patients call for more support, training

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

At least 13 dead in Texas as scorching temps continue

Novartis develops a rapidly manufactured CAR

Moonlake's readout produced a cash windfall. Risks remain

The nurse manager staffing crisis is hurting patients

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How to protect coverage of PrEP

hotspot

New requirements coming in 2024 for Americans traveling to Europe

JPM 2024: Verve Therapeutics looks to mainstream genome editing

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Biotech reporter’s notebook: A sunnier mood at JPM 2024

entertainment

focus

hotspot

entertainment